SC
JSPR icon

Shay Capital’s Jasper Therapeutics JSPR Stock Holding History

Shay Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$188K – 372
2024
Q3 		$188K Sell
10,000
-6,357
-39% -$127K 0.03% 255
2024
Q2 		$371K Buy
+16,357
New +$392K 0.05% 170

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Shay Capital's JSPR Position: Q4 2024 in Review

Shay Capital sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 10,000 shares — an estimated $188K sold.

Shay Capital first reported a position in JSPR in Q2 2024 and held it in 2 quarters. The position peaked at $371K in Q2 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

  • Shay Capital reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Shay Capital sold 10,000 Jasper Therapeutics shares in Q4 2024, an estimated $188K.
  • Shay Capital first reported a position in Jasper Therapeutics in Q2 2024 and held it in 2 quarters.
  • Shay Capital's Jasper Therapeutics position peaked at $371K in Q2 2024.
  • 87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on Shay Capital's 13F filing for Q4 2024, filed 14 Feb 2025.